Literature DB >> 2163428

Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys.

V J Lotti1, N Pawlowski.   

Abstract

MK-422 (enalaprilat) (0.0005-0.5%) significantly reduced intraocular pressure (IOP) in African Green monkeys. Studies utilizing unilateral instillation of MK-422 and its inactive R-isomer indicated a local site of action within the eye which is dependent upon inhibition of angiotensin converting enzyme, also known as kininase II. Tonography showed a small increase (21%) in conventional aqueous humor outflow facility which did not entirely account for the IOP lowering effect of MK-422. Pretreatment with indomethacin or pilocarpine specifically attenuated the ability of MK-422 to lower IOP suggesting that biosynthesis of prostaglandins and uveoscleral outflow pathways are important in mediating the ocular hypotension. The data indicate that MK-422 may lower IOP in monkeys by virtue of its ability to prevent the breakdown of bradykinin and thereby promote the formation of endogenous prostaglandins in the eye.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163428     DOI: 10.1089/jop.1990.6.1

Source DB:  PubMed          Journal:  J Ocul Pharmacol        ISSN: 8756-3320


  9 in total

Review 1.  Deconstructing aqueous humor outflow - The last 50 years.

Authors:  Paul L Kaufman
Journal:  Exp Eye Res       Date:  2020-06-23       Impact factor: 3.467

2.  Advances in glaucoma treatment and management: outflow drugs.

Authors:  Paul L Kaufman; Carol A Rasmussen
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

3.  Differences in corneal parameters between normal tension glaucoma and primary open-angle glaucoma.

Authors:  Jacky W Y Lee; Raymond L M Wong; Jonathan C H Chan; Ian Y H Wong; Jimmy S M Lai
Journal:  Int Ophthalmol       Date:  2014-11-25       Impact factor: 2.031

4.  Local ocular renin-angiotensin-aldosterone system: any connection with intraocular pressure? A comprehensive review.

Authors:  Mervi Holappa; Heikki Vapaatalo; Anu Vaajanen
Journal:  Ann Med       Date:  2020-04-30       Impact factor: 4.709

5.  Physicochemical and Stability Evaluation of Topical Niosomal Encapsulating Fosinopril/γ-Cyclodextrin Complex for Ocular Delivery.

Authors:  Hay Marn Hnin; Einar Stefánsson; Thorsteinn Loftsson; Rathapon Asasutjarit; Dusadee Charnvanich; Phatsawee Jansook
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

6.  Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma.

Authors:  Kazuyuki Hirooka; Fumio Shiraga
Journal:  Clin Ophthalmol       Date:  2007-09

7.  Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats.

Authors:  Giselle Foureaux; Juçara Ribeiro Franca; José Carlos Nogueira; Gustavo de Oliveira Fulgêncio; Tatiana Gomes Ribeiro; Rachel Oliveira Castilho; Maria Irene Yoshida; Leonardo Lima Fuscaldi; Simone Odília Antunes Fernandes; Valbert Nascimento Cardoso; Sebastião Cronemberger; André Augusto Gomes Faraco; Anderson José Ferreira
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

Review 8.  Therapeutic targets of renin-angiotensin system in ocular disorders.

Authors:  Rajesh Choudhary; Mandeep Singh Kapoor; Amrita Singh; Surendra H Bodakhe
Journal:  J Curr Ophthalmol       Date:  2016-10-20

Review 9.  Many Faces of Renin-angiotensin System - Focus on Eye.

Authors:  Mervi Holappa; Heikki Vapaatalo; Anu Vaajanen
Journal:  Open Ophthalmol J       Date:  2017-06-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.